Analysing lymphokine-receptor interactions of IL-1 and IL-2 by recombinant-DNA technology.
The development of lymphokines as pharmaceutical agents is at the forefront of current biotechnological research. Lymphokines exert their regulatory action on cellular function through interaction with cell-surface receptors. An understanding of the biochemical nature of these molecular interactions should facilitate the design of small peptide analog pharmaceuticals which mimic lymphokines or their receptors.
DNAX Research Institute of Molecular and Cellular Biology Inc., Palo Alto, CA 94304-1104.
G
G
Zurawski
D000595:Amino Acid Sequence; D000818:Animals; D004274:DNA, Recombinant; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics / Q000378:metabolism*; D007376:Interleukin-2 / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D016296:Mutagenesis; D011971:Receptors, Immunologic / Q000235:genetics / Q000378:metabolism*; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2 / Q000235:genetics / Q000378:metabolism*
D004274:DNA, Recombinant; D007375:Interleukin-1; D007376:Interleukin-2; D011971:Receptors, Immunologic; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2